BMS boosts neurodegenerative drug pipeline with iPierian buy

Bristol-Myers Squibb agreed to purchase South San Francisco, Calif.-based firm iPierian for $175 million in cash plus up to $550 million in milestone fees. The deal is expected to strengthen Bristol's neurodegenerative drug pipeline as it gains rights to iPierian's experimental drugs designed to fight tau proteins related to Alzheimer's disease and other neurodegenerative disorders. "The acquisition of iPierian supports our growing efforts in this area and builds on Bristol-Myers Squibb's internal expertise and alliances focused on the Tau pathway and neurodegenerative diseases," Bristol's Executive Vice President and Chief Scientific Officer Francis Cuss said.

View Full Article in:

Genetic Engineering & Biotechnology News · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care